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ORIGINAL ARTICLE

Leptin deﬁcient ob/ob mice and diet-induced obese mice
responded differently to Roux-en-Y bypass surgery
Z Hao1, H Münzberg1, K Rezai-Zadeh1, M Keenan2, D Coulon2, H Lu3, H-R Berthoud1 and J Ye1
OBJECTIVE: Weight regain contributes to the therapeutic failure in 15–20% of type 2 diabetic patients after Roux-en-Y gastric
bypass surgery (RYGB), and the mechanism remains largely unknown. This study was conducted to explore the mechanism of
weight regain.
RESEARCH DESIGN: Wild-type (WT) diet-induced obese (DIO) mice were used to mimic human obesity, and ob/ob mice were used
for leptin deﬁciency-induced obesity. Two groups of mice were compared in weight regain for 10 months after RYGB. Weight loss,
food intake, fecal energy loss and energy expenditure were monitored in the study of weight regain. Fasting insulin, insulin
tolerance and homeostatic model assessment-insulin resistance were tested for insulin sensitivity under the weight regain. Weight
loss from RYGB and calorie restriction was compared for the impact in insulin sensitivity.
RESULTS: In WT mice, RYGB induced a sustained weight loss and insulin sensitization over the sham operation in this 10-month
study. However, RYGB failed to generate the same effects in leptin-deﬁcient ob/ob mice, which suffered a weight regain over the
pre-surgery level. In ob/ob mice, body weight was reduced by RYGB transiently in the ﬁrst week, recovered in the second week and
increased over the baseline thereafter. Weight loss was induced by RYGB relative to that of sham mice, but the loss was not
sufﬁcient to keep body weight below the pre-surgery levels. In addition, insulin sensitivity was not improved by the weight loss.
The response to RYGB was improved in ob/ob mice by 2 weeks of leptin treatment. Weight loss from calorie restriction had an
equivalent effect on insulin sensitization compared with that of RYGB.
CONCLUSION: Those data demonstrate that ob/ob mice and DIO mice responded differently to RYGB surgery, suggesting that
leptin may be one of the factors required for RYGB to prevent weight regain and diabetes recurrence.
International Journal of Obesity (2015) 39, 798–805; doi:10.1038/ijo.2014.189

INTRODUCTION
Roux-en-Y gastric bypass surgery (RYGB) is among the most
effective bariatric surgeries in producing sustained decrease in
body weight and remission of type-2 diabetes.1,2 In addition, RYGB
improves most of the deleterious comorbidities associated with
severe obesity.2 Despite intensive efforts, the critical mechanisms
responsible for these beneﬁcial effects of RYGB have not yet been
clearly identiﬁed. Ultimately, RYGB must change patterns of
humoral and neural signaling between the gastrointestinal system
and other organs (such as the brain, liver, adipose tissue and so
on) involved in the energy regulation.3,4 Much attention has been
given to changes in circulating gut hormones, such as glucagonlike peptide 1 (GLP-1),5,6 peptide tyrosine tyrosine (PYY)7,8 and
ghrelin9 in mechanistic studies. However, recent ﬁndings in
various rodent models have provided relatively little support for
their critical roles in the effects of RYGB,10–14 although synergistic
actions between these hormones and other factors have not been
excluded.
It has also become clear that the negative energy balance after
RYGB does not result from an inability to increase energy intake. If
RYGB rodents were properly stimulated, food intake can easily be
doubled leading to substantial weight regain.10,15,16 Also, 15–20%
of RYGB patients return to pre-surgical levels of food intake and
regain body weight in spite of their rearranged gut.1 One
interpretation of these observations is that successful surgery
1

establishes a new lower level of body weight that is actively
defended after RYGB. This function is classically ascribed to the
hypothalamus, where leptin and other feedback signals regulate
energy balance by orchestrating the necessary changes in energy
intake and expenditure.17 It is not clear if leptin contributes to the
defense of post-surgery low body weight.
Leptin resistance contributes to hyperphagia and hypometabolism in obesity. Serum leptin is increased by obesity and reduced
by RYGB,5,18 suggesting an increase in leptin sensitivity. However,
it is largely unknown if leptin has a role in the control of weight
regain after RYGB.4 In two early studies of leptin receptor-deﬁcient
Zucker obese rats, RYGB induced weight loss and insulin
sensitization immediately post surgery.19,20 However, the longterm effect of RYGB was not examined in these studies for weight
regain.
The present study was designed to test the impact of leptin in
the long-term effects of RYGB with a focus on weight regain and
glycemic control. We have recently established a valid mouse
RYGB model, characterized by a small gastric pouch, sustained
suppression of body weight below the pre-surgical level, and low
mortality.10,21 Here, we take advantage of this model to study
weight regain and glycemic control for 10 months after RYGB in
diet-induced obese (DIO) mice and leptin-deﬁcient ob/ob. In
addition, leptin-replacement therapy was tested in ob/ob mice for
2 weeks at 25 weeks after RYGB.
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MATERIALS AND METHODS
Obese mice

limb and the biliopancreatic limb were ~ 5–6 cm in length. The intestine
was arranged in an ‘S’ position to avoid intestinal obstruction before
closing of the abdominal cavity. In sham operation, the perigastric
ligaments were cut, and a 3-mm incision was made in the stomach closed
with a titanium clip. The jejunum was transected 2 cm distal to the
ligament of Treitz, and the two cut ends were anastomosed. Standard
aseptic procedures were used throughout. In the ﬁrst 24 h after the
operation, the mice were put in regular shoe box cages on a heating
pad at 35 °C. The mice were given 0.8 ml per mouse of saline
subcutaneously and carprofen (5 mg kg−1, sc) for analgesia immediately
after surgery. The mice had access to water and solid diet right
after surgery. Post-surgical survival rates were 90% in DIO mice and 80%
in ob/ob mice.

All experiments were approved by the Institutional Animal Care and Use
Committee of Pennington Biomedical Research Center. Animals were
housed under conventional conditions at the Pennington Animal Facility.
In the study design, wild-type (WT) male C57BL/6J mice were used in DIO
group and chow-fed group (lean control). DIO mice were generated by
feeding 6-week-old mice with a high-fat diet (HFD, D12331 diet, 58%
calories from fat, Research Diets Inc.) for 14 weeks. Then, the DIO mice
were divided into three subgroups (n = 7): DIO+RYGB, DIO+sham and DIO
+weight matched. The lean control mice (n = 7) were fed regular chow diet
(11% calorie from fat, 5001 LabDiet) ad libitum. After surgery, DIO mice
were fed a medium-fat diet (25% calorie from fat, 5015 LabDiet) to reﬂect
diet condition in patients. DIO+weight-matched group were subject to
food restriction at 14 weeks of HFD feeding to induce an identical weight
loss to that of DIO+RYGB group. Forty C57BL/6 mice were used to
generate the models and 28 mice were left after excluding unqualiﬁed
DIO mice and dead mice in surgery. Male ob/ob mice (26 mice) in C57BL/6
gene background were purchased from the Jackson Laboratory at
4–7 weeks in age and fed the regular chow diet ad libitum before and
after the surgery.

Physiological parameters
Body weight, body composition and food intake were measured in this
study as described elsewhere.21 The body weight was determined daily in
the ﬁrst 2 weeks and then weekly after the surgery. Body composition was
determined using nuclear magnetic resonance in each cohort at times
indicated in Figure 1. Food intake was determined in single-housed mouse
manually or using the metabolic chamber for 1–2 weeks.

Surgical procedures
RYGB surgery was performed in DIO mice at 14 weeks on HFD with a body
weight of 46 ± 5 g. The surgery was performed in ob/ob mice at 6 week
(35 g) and 10 week (50 g) in age. The surgery operation was conducted as
described in detail earlier.21 In brief, animals were fasted 4–6 h before the
operation and anesthesia was administrated with isoﬂurane inhalation. In
RYGB surgery, the anterior and posterior left gastric vessels, as well as the
esophageal vessels, were ligated and cut. A small gastric pouch at 5% of
the total gastric volume was generated and anastomosed with the
jejunum by 16–18 interrupted stiches with 11–0 nylon suture. The Roux
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Indirect calorimetry measurement was performed with the Comprehensive
Laboratory Animal Monitoring System (Columbus Instruments, Columbus,
OH, USA) for individually housed mice as described in detail earlier.22 After
96 h of adaptation, the data for oxygen consumption (VO2), carbon dioxide
production (VCO2), respiratory exchange ratio and spontaneous physical
activity were simultaneously recorded and analyzed.22 The data of day and
night are presented.
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Figure 1. Body weight and fat content after RYGB. (a) Body weight of WT mice (DIO). The mice were divided into four groups: chow diet
control (Chow Ctrl), Sham-operated, RYGB and weight matched (Wt match). The mice were fed HFD before surgery and the breeder chow
(medium fat) diet after surgery. RYGB was performed in the mice around 14 wks on HFD. Body weight was monitored weekly in the ﬁrst 4 wks
and then biweekly for 39 wks. Body composition and energy expenditure (EE) were tested at 7 wks. Food choice test was conducted at 16 wks,
where the mice had free access to the HFD and the regular chow diet for 6 wks. ITT was tested at 35 wks (N = 7 Chow Ctrl, 7 Sham, 7 RYGB,
7 Wt match). (b) ob/ob mice (6-wk-old group, n = 5). RYGB was performed in the mice at 6 wks in age. Body weight was monitored for 39 wks
with composition test at 3 wks, food intake at 6–7 wks, and EE at 8–9 wks post surgery. (c) ob/ob mice (10-wk-old group, n = 6). RYGB was
performed in the mice at 10 wks in age. The body weight was monitored for 27 wks with ITT at 11 wks, EE at 19 wks and leptin treatment at 25
wks. (d) Percentage weight loss after RYGB. WT and ob/ob mice were compared in percentage weight loss after RYGB at three time points as
indicated. (e) Body fat content of WT mice. Body composition was monitored at 8 wks after RYGB (N = 8 Chow, 7 Sham, 8 RYGB, 7 Wt match).
(f) Body fat content of ob/ob mice (6-wk-old group). The body composition was measured at 3 wks after RYGB (n = 5). The data are expressed
as mean ± s.e. *P o0.05, ***Po0.001 vs before surgery or calorie restriction by t-test.
© 2015 Macmillan Publishers Limited
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Fecal calorie content
Fecal samples were collected for each mouse after surgery and stored in
− 80 oC. The caloric content was determined using a Parr 1266 Isoperibol
Bomb Calorimeter (Parr Instrument Company, Moline, IL, USA). Approximately 1 gm fecal samples were freeze dried to remove all moisture. For
each 1 gm fecal sample, an aliquot of ~ 0.2–0.3 grams were processed in
the bomb calorimeter. Hexadecane (Sigma-Aldrich, St Louis, MO, USA), a
combustible spiking agent, was added to each sample to ensure complete
combustion of the entire fecal sample. A heat of combustion value is
obtained for each fecal sample in calories per gram after 8 min. The value
was corrected for combustion heat of the spiking agent automatically and
a ﬁnal gross heat value was used for the fecal calorie. Each sample was run
in duplicate trials in order to obtain an average value.

Insulin, leptin and insulin tolerance test
Blood was collected from mice through retro-optical bleeding at 6 weeks
post surgery after overnight fasting. Serum insulin and leptin were tested
using multiplex kit (MMHMAG-44K, Millipore Corporation, 28820 Single
Oak Drive, Temecula, California). Insulin tolerance was performed in each
cohort at times indicated in Figure 1. The test was conducted with
peritoneal injection of insulin at 0.7 U Kg − 1 after 4 h fasting. MOHA-IR was
calculated with a formula: homeostatic model assessment-insulin resistance (mg dl − 1) = glucose × insulin/405.

Leptin injection
For long-term leptin effects on RYGB ob/ob mice, leptin was intraperitoneally injected twice daily over 2 weeks at a dosage 1 mg kg − 1 per day.
Food intake and body weight was monitored daily using the BioDaq cage
system.

Statistical analysis
In this study, values are presented as mean ± s.e.m. Student’s t-test was
used in most data analysis for body weight, insulin tolerance, energy
expenditure, substrate utilization and body temperature. Two-way ANOVA
was performed in the study of leptin sensitivity followed by a post hoc
analysis. P-values o0.01 were considered signiﬁcant.

RESULTS
RYGB prevented weight regain in WT, but not ob/ob mice
In the DIO model that was generated in WT C57BL/6 mice, RYGB
surgery was performed at 14 weeks on HFD when the body
weight was around 50 g. DIO mice exhibited a persistent weight
loss after RYGB (Figure 1a). Most weight reduction was observed in
the ﬁrst 2 weeks post surgery and the weight loss was about 35%
at the end of 3 weeks. At this time, WT mice lost all of the weight
gain on HFD. Thereafter, the RYGB mice shared an identical body
weight to the chow diet group in the entire 39-week study
without weight regain (Figure 1a). ob/ob mice were tested in RYGB
in two cohorts at different ages, 6 weeks (35 g) and 10 weeks
(50 g), to determine the impact of pre-surgery body weight in the
surgery effect. In the ﬁrst cohort, a transient weight loss was
observed in the 6-week group with 4 g weight reduction in the
ﬁrst week post-surgery (Figure 1b). Interestingly, a persistent
weight gain was observed in the mice thereafter. The body weight
became 20% above the pre-surgical levels 8 weeks post-surgery
(Figures 1b–d). Compared with sham-operated mice, RYGB mice
exhibited less weight regain after surgery. In the second cohort, a
similar pattern of weight regain was observed in 10-week-old ob/
ob mice although the pre-surgery body weight was much higher
(Figure 1c). Percentage weight loss was compared between WT
and ob/ob mice at 1, 3 and 8 weeks post surgery. Persistent
weight loss beyond pre-surgery levels was only observed in WT
mice, but not in ob/ob mice after RYGB (Figure 1d). ob/ob mice
exhibited some weight loss after 10 weeks of RYGB in the second
cohort, which might be a consequence of stress responses from
the tests, such as insulin tolerance test and metabolic chamber
study. Even though, the body weight remained above the presurgery levels (Figure 1c). Such a weight reduction was not
International Journal of Obesity (2015) 798 – 805

observed in the sham ob/ob mice, suggesting that RYGB may
increase ob/ob mouse sensitivity to stressful challenges. These
data suggest that in contract to that in WT mice, RYGB could not
prevent weight regain in ob/ob mice.
Body fat reduction accounts for the surgery-induced weight
loss. Fat mass was measured using nuclear magnetic resonance in
WT and ob/ob mice. DIO mice exhibited 40% reduction in fat mass
8 weeks after RYGB (Figure 1d). A portion of the reduction was a
result of switching from high-to-medium-fat diet after surgery, as
about 9% weight reduction was also observed in sham-operated
WT mice. HFD was replaced by the medium-fat diet (breeder
chow) after surgery to reﬂect diet preference in RYGB patients and
to maintain the adiposity. ob/ob mice did not exhibit a reduction
in fat mass after RYGB as indicated by data in the ﬁrst cohort
(Figure 1f). Instead, fat mass was increased over the pre-surgery
levels in both sham and RYGB ob/ob mice. The data suggest that
RYGB fails to reduce fat mass below pre-surgery levels persistently
in ob/ob mice.
NRYGB increased energy expenditure in WT, but not ob/ob mice
Energy intake, fecal energy loss and energy expenditure were
examined at 5–8 weeks after RYGB when the body weight was
stabilized at the lower level in DIO mice. Daily food intake per
mouse was not signiﬁcantly reduced by RYGB in DIO mice
(Figure 2a). A modest reduction was observed in ob/ob mice after
RYGB (Figure 2a), but the change is not signiﬁcant. Fecal calorie
content was signiﬁcantly increased by RYGB in both WT and ob/ob
mice (Figures 2b and c). Serum leptin was signiﬁcantly decreased
in WT mice by RYGB or calorie restriction in weight-matched
group (Figure 2d). Energy expenditure per lean body mass was
signiﬁcantly increased by RYGB in WT, but not in ob/ob mice
(Figures 3a and b). To the contrary, energy expenditure was
decreased by RYGB in ob/ob mice (Figure 3b). The decrease was
observed when the data were normalized with either lean body
mass (Figure 3b) or whole-body weight (Figure 3c). The decrease
was signiﬁcant at day and night time when normalized with
lean mass, but only night time when normalized with wholebody mass. The difference between WT and ob/ob mice
suggests that RYGB was not able to induce energy expenditure
in ob/ob mice.
RYGB improved insulin sensitivity in WT, but not ob/ob mice
Insulin sensitivity was examined with fasting insulin and insulin
tolerance in this study. In WT mice, serum insulin was increased by
obesity ﬁve- to sixfold (Figure 4a, sham). The insulin was restored
to the level of lean control mice by RYGB at 6 weeks post surgery
(Figure 4a, RYGB). The same reduction was observed in weightmatched DIO mice (Figure 4a, Wt-matched). However, the RYGB
effect was not observed in ob/ob mice (Figure 4b). In insulin
tolerance test, a similar improvement was observed in WT mice
after RYGB or calorie restriction (Figures 4c and d). A signiﬁcant
improvement was not observed ob/ob mice after RYGB (Figures
4e and f). The data suggest that RYGB improves insulin sensitivity
in WT, but not in ob/ob mice.
To test the weight-dependent effect of RYGB on insulin
sensitivity, weight-matched mice were compared with RYGB mice
in insulin sensitivity, which was conducted in WT mice (Figure 1).
After calorie restriction, the weight-matched group exhibited
identical improvement in insulin sensitivity to RYGB group in
terms of changes in fasting insulin and insulin tolerance (Figures
4a–c), suggesting that weight loss from RYGB is critical in the
maintenance of insulin sensitivity.
Leptin restored RYGB effects in ob/ob mice
To test leptin in the effects of RYGB, we administrated leptin in
ob/ob mice (1 mg kg − 1 per day, i.p.) in a 2-week study. Body weight,
© 2015 Macmillan Publishers Limited
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Figure 2. Energy intake and fecal calorie content after RYGB. (a) Energy intake of WT and ob/ob mice. The mice were single housed and food
intake was measured for 3 days after 4 day adaptation. The food intake was conducted at 6 wks post surgery and expressed in kcal per day per
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fasting blood at 6 wks after RYGB. The data are expressed as mean ± s.e. ***Po0.001 vs sham control by t-test.
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food intake and insulin sensitivity were monitored in the study.
Reduction in body weight and food intake was observed in both
sham and RYGB mice following leptin treatment (Figures 5a and b).
The weight reduction was identical in mass (g) in the two groups.
However, percentage weight loss was signiﬁcantly larger in the
RYGB group because of lower body weight. The reduction in food
intake was signiﬁcantly more (51%) in the RYGB group compared
with the sham group (Figure 5c). Insulin sensitivity was measured
by fasting insulin and homeostatic model assessment-insulin
resistance. More Improvement was observed in RYGB mice
after the leptin treatment (Figures 5d–f). Fasting blood glucose
was not signiﬁcantly different in the two groups of mice after the
leptin treatment (Figure 5e). These data suggest that leptin
injection signiﬁcantly improves ob/ob mouse response to RYGB
surgery.
DISCUSSION
Our mouse model of RYGB allowed us to compare ob/ob mice and
DIO mice in RYGB surgery. The model is characterized by the close
International Journal of Obesity (2015) 798 – 805

similarity with RYGB surgery in humans, including the ~ 35%
sustained weight reduction and insulin sensitization for up to 39
(10 months) weeks (equivalent to ~ 20 years in humans) and low
mortality. These effects are coupled with a negative energy
balance in DIO mice after RYGB.
ob/ob mice failed to exhibit substantial weight loss after RYGB
surgery. The mice exhibited a transient weight loss of ~ 10% in the
ﬁrst week post surgery, but the loss disappeared in 2 weeks after
the surgery, which was associated with a sustained weight regain.
Although the body weight exceeded pre-surgery level after
3 weeks in RYGB group, the weight regain was much less than
that of sham group, suggesting that RYGB delayed weight gain in
ob/ob mice. The reduction in nutrient absorption may contribute
to the delay in RYGB mice. However, the nutrient reduction was
not sufﬁcient to keep the body weight below the pre-surgery level
in ob/ob mice. In clinical practice, weight reduction beyond the
pre-surgery level is used to determine the therapeutic effects of
bariatric bypass surgeries.1 A systematic review and meta-analysis
of large sets of published data suggest that RYGB therapy fails to
improve glucose metabolism in 15–20% obese patients.1 In light
© 2015 Macmillan Publishers Limited
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of this criterion, our data suggest that the leptin signal may be
required for prevention of weight regain in RYGB.
RYGB fails to enhance energy expenditure in ob/ob mice.
Leptin, a hormone produced by adipose tissue, inhibits food
intake and stimulates energy expenditure. Lack of leptin makes
ob/ob mouse an excellent model to test leptin in RYGB. Although
the hypothalamic circuitry is altered in ob/ob mice,23 the neuron
response to leptin is not inﬂuenced by the alteration24 and leptin
is able to restore the metabolic disorders in ob/ob mice.25 Energy
expenditure was increased by RYGB in DIO mice, but not in ob/ob
mice, suggesting that lack of leptin is responsible for the low
energy expenditure in ob/ob mice. Leptin sensitivity was
decreased by obesity, and improved by RYGB as suggested by
serum leptin alteration in DIO mice in this study. The improvement
is translated into sustained weight loss in DIO mice, but not in
ob/ob mice. Leptin is required by RYGB to enhance energy
expenditure and decrease body weight.
ob/ob mice failed to show persistent improvement in insulin
sensitivity after RYGB. In ob/ob mice, insulin sensitivity was tested
with insulin tolerance test and homeostatic model assessmentinsulin resistance. Blood glucose was increased instead of
decreasing after insulin injection in insulin tolerance test
(Figure 4e). The increase is likely a result of stress response under
severe insulin resistance in ob/ob mice, which prevent insulin
action in the reduction of glucose. Our data suggest that RYGB
was unable to improve insulin sensitivity in ob/ob mice. However,
the improvement was observed after the 14 day leptinreplacement therapy, suggesting that leptin may be required for
the improved insulin sensitivity after RYGB. In DIO model, insulin
sensitivity was improved to the same level in the RYGB and WTmatched groups with identical weight loss, suggesting that the
weight loss is critical for the sustained insulin sensitization after
RYGB. Although the weight-matched strategy was not used in the
study of ob/ob mice, the weight loss-dependent effect may apply
© 2015 Macmillan Publishers Limited

to ob/ob mice as well. In leptin therapy, the more improvement in
insulin sensitivity was coupled with a larger reduction in food
intake in RYGB ob/ob mice, supporting the role of negative energy
balance in the control of insulin sensitization. Several recent
reports suggest that the negative energy balance from calorie
restriction has an equivalent effect to RYGB on improving insulin
sensitivity in patients.6–28 Future experiments with different doses
of leptin and clamp techniques will be necessary to shed light on
the mechanisms of insulin sensitization in ob/ob mice by RYGB.
This study suggests that the intact function of leptin circuitry
may be required for RYGB effects. The leptin signaling pathway
includes multiple proteins such as leptin receptor, melanocortin 4
receptor (MC4R), agouti-related protein and peptide tyrosine
tyrosine. In the pathway, leptin binds to the receptor in
proopiomelanocortin neurons to induce the secretion of
melanocyte-stimulating hormone (α-MSH) and β-MSH. α-MSH
activates MC4R to increase cAMP in the neurons for sensation of
satiety. Leptin also inhibits expression of neuropeptide Y and
agouti-related protein, which induce food intake. Agouti-related
protein stimulates appetite through the inhibition of MC4R.29
Mutation in any of the signaling proteins may lead to functional
deﬁciency of the leptin signaling pathway. Our study suggests
that a defect in the leptin signaling pathway may decrease the
efﬁcacy of RYGB surgery. Although leptin mutation is rare in
humans, mutations in the downstream signaling proteins are
often found in severe obese patients.30 MC4R mutation is
associated with severe obesity31 and loss of MC4R function
attenuates the effects of RYGB surgery.32 The MC4R activity has
been veriﬁed in MC4R knockout mice, which failed to respond to
RYGB surgery.33 In two previous studies of Zucker obese rats
(leptin receptor deﬁcient), RYGB decreased body weight below
pre-surgery level.19,20 It is not clear which of the many differences
(species, surgery, diet, and timeline) between this and other
studies accounts for the discrepant outcome in body weight.
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While, 4 weeks may have been too short to detect weight regain
in Zucker rats after RYGB, particularly with a small (about 14%)
weight loss at 4 weeks in one study.20 Leptin may not be the only
factor in the prevention of weight regain. There are other factors
contributing to the weight control by RYGB, such as bile acid that
signals via the farnesoid X receptor,34 re-programming of gut
glucose utilization35 and increased levels of circulating peptide
tyrosine tyrosine.8 As ob/ob mouse is fragile and easily stressed, it
was quite a challenge to keep mortality low after RYGB. Carefully
maintaining body temperature and hydration levels during
surgery and immediate post surgery was crucial.
In conclusion, our data demonstrate the difference of ob/ob
and DIO mice in response to RYGB surgery. In DIO mice, RYGB
generated a persistent weight loss and insulin sensitization like
what have reported in 80–85% obese patients in the clinical
studies. In ob/ob mice, although RYGB attenuated weight gain
compared with sham operation, it failed to keep the body weight
below the pre-surgery level. The weight regain resembles what
has been reported in obese patients with MCR4 mutation after
RYGB. Our observations suggest that leptin sensitivity is improved
by RYGB. The improvement is translated into sustained weight loss
in DIO mice, but not in ob/ob mice. Leptin appears to be one of
the endocrine factors required for the therapeutic effects of RYGB
surgery. Lack of leptin or dysfunction of leptin signaling circuitry
may contribute to the weight regain and diabetes recurrence in
15–20% obese patients after RYGB surgery. This study re-enforces
that weight loss contributes substantially to insulin sensitization in
RYGB. These conclusions may help to predict efﬁcacy of RYGB
surgery before the surgery, and explain the weight regain after
surgery.
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